Argos Therapeutics, Inc. (NASDAQ:ARGS) rose 0% on Monday . The company traded as high as $0.21 and last traded at $0.20. Approximately 4,735,914 shares traded hands during trading, an increase of 101% from the average daily volume of 2,352,781 shares. The stock had previously closed at $0.20.
Separately, Zacks Investment Research downgraded Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating and three have given a hold rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $4.13.
The company has a debt-to-equity ratio of -1.46, a quick ratio of 2.29 and a current ratio of 2.29.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.